key: cord-0710652-659ymjny
authors: Sumida, Yoshio; Yoneda, Masashi
title: COVID-19-associated liver injury (COVALI): role of hepatologists
date: 2021-07-02
journal: J Gastroenterol
DOI: 10.1007/s00535-021-01809-9
sha: 7660b69a041377063c0f40b7ad91862e064e128c
doc_id: 710652
cord_uid: 659ymjny

nan

We read with great interest the article by Li and colleagues [1] . COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has become a global pandemic. Elevated hepatic enzymes are common in patients with COVID-19, occurring in approximately 15-65% of SARS-CoV-2-infected individuals, particularly in severe cases. Liver biopsy results in patients with SARS-CoV-2 have been characterized by non-specific findings, including steatosis, mild lobular and/or portal inflammation, and vascular pathology. It still remains unknown SARS-CoV-2 can directly infect hepatocytes and/or cholangiocytes. Mechanisms underlying COVID-19-associated liver injury (COVALI) are multifactorial and related to direct cytopathic effect of SARS-CoV-2, cytokine storm, hypoxia, abnormal coagulation, an administrated drug, and preexisting chronic liver diseases (CLD). The article extensively reviewed plausible mechanisms of COVALI. Overall, 2-11% of patients with COVID-19 were reported to have underlying CLD. Patients with cirrhosis have high rates of hepatic decompensation, acute-on-chronic liver failure and death from respiratory failure following SARS-CoV-2 infection and should be prioritized for COVID-19 vaccination. The Asia Pacific Association for the Study of the Liver (APASL) launched a pan-Asia collaborative study ''APASL COVID Liver Injury Spectrum (APCO-LIS). APCOLIS study showed that the outcome was poor with Child-Pugh score 9 or more among 43 cirrhosis those exposed to SARS CoV2 infection [2] . According to data on 745 patients with CLD and SARS-CoV-2 from a UK hospital network. Baseline child stage and alcohol-related liver disease are independent risk factors for death from COVID-19 [3] . Accumulating evidences have proposed that metabolism-associated fatty liver disease may be a risk factor for COVID-19 severity. Liver transplant recipients do not appear to have an increased risk of mortality following SARS-CoV-2 infection compared with the matched general population. The effects of COVID-19 on underlying CLD require detailed evaluation, with further research warranted in this area. Remdesivir, an approved drug for patients with COVID-19, may have hepatotoxic effects. Remedesivir should not be used for COVI-19 patients with baseline liver enzymes more than five times the upper limits or decompensated cirrhosis. If patients with COVID-19 receive dexamethasone or tocilizumab, HBV reactivation should be ruled out. International academic societies have recommended guidance outlining the evidence to date regarding the management of patients with COVID-19 and liver disorders, and CLD under the COVID-19 pandemic. The percentages of scheduled visits to screen HCC or varices in chronic hepatitis C after sustained virologic response declined rapidly after COVID-19 became pandemic in Japan [4] . We should avoid delay of HCC surveillance in CLD patients. If liver enzymes are commonly elevated in patients with COVID-19, we should first evaluate for the presence of other causes including acute viral infections (HAV, HBV, HEV, etc.) or pre-existing This comment refers to the article available online at https://doi.org/ 10.1007/s00535-021-01760-9. CLD, and strictly follow-up liver enzyme values. Hepatologists must play a certain important role in management of COVALI in collaboration with respiratory medicine and infectious disease specialists until efficacious SARS-CoV2 vaccines or effective medications are globally available [5] .

Conflict of interest The authors declare that they have no conflict of interest.

COVID-19-associated liver injury: from bedside to bench

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study

Impact of COVID-19 pandemic on surveillance of hepatocellular carcinoma: a study in patients with chronic hepatitis C after sustained virologic response

Relationship between COVID-19 and liver diseases: the role of hepatologists in clinical practice

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations